MARKET

LLY

LLY

Lilly Eli & Co
NYSE
759.91
+25.34
+3.45%
Opening 13:04 05/12 EDT
OPEN
727.87
PREV CLOSE
734.57
HIGH
761.77
LOW
722.18
VOLUME
6.44M
TURNOVER
--
52 WEEK HIGH
969.25
52 WEEK LOW
677.09
MARKET CAP
720.19B
P/E (TTM)
61.78
1D
5D
1M
3M
1Y
5Y
1D
Roche plans $700M North Carolina facility
Seeking Alpha · 2h ago
Innovation, pharma profits won't suffer under Trump prescription drug EO - White House
Seeking Alpha · 3h ago
Trump Executive Order Could Reshape How Americans Pay for Drugs. It's Not Bad for Pharma.
Barron‘s · 3h ago
Pharma Stocks Hit by Trump's Vow to Cut US Prescription Drug Costs
NASDAQ · 3h ago
Wall Street Rips Higher As Tariff Truce Halts US–China Economic Escalation
Benzinga · 3h ago
4 stocks to watch on Monday: AAPL, NRG, FOX/FOXA and LLY
Seeking Alpha · 3h ago
Eli Lilly Says Trial Patients Lost More Weight on Zepbound Than Rival's Wegovy
Dow Jones · 4h ago
'Trump To Sign Order To Cut Some U.S. Drug Prices To Match Those Abroad' - CNBC
Benzinga · 4h ago
More
About LLY
More
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity, and Zepbound. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing efforts, as well as clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD). It also owns a lead therapeutic molecule, FXR314.
Recently
Symbol
Price
%Change
    LLY
  • 759.91
  • +3.45%

Webull offers Eli Lilly And Co stock information, including NYSE: LLY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LLY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LLY stock methods without spending real money on the virtual paper trading platform.